Accreditation Number : CAP2305SYPJH
Group 1 : 1 CPD credits
Group 2 : 2 CPD credits
This activity has been accredited for 1 hours of Group 1 CPD (or 1 CPD credits) suitable for inclusion in an individual pharmacist's CPD plan, which can be converted to 1 hours of Group 2 CPD (or 2 CPD credits) upon successful completion of relevant assessment activities.
Ping, 45, is a regular patient of the pharmacy and presents a repeat script for nortriptyline. He has had a partial response to this medicine, reporting improvements in chronic pain. When you inquire about any potential new medicines, he mentions he recently visited a new GP who prescribed a trial of a THC-dominant medicinal cannabis flower dried for vaporization, which he is yet to have dispensed. The new GP was not aware of his nortriptyline use.
After completing this activity pharmacists should be able to:
- Describe the most common indications medicinal cannabis-based products (CBPs) are prescribed for in Australia
- Explain the common mechanisms whereby cannabis and CBPs may interact with other medicines
- Discuss examples of clinically observed drug interactions between CBPs and commonly co-prescribed medicines
- Discuss the role of the pharmacist in reviewing for and identifying a
THIS IS A CPD ARTICLE. YOU NEED TO BE A PSA MEMBER AND LOGGED IN TO READ MORE.